Callan Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Callan Capital’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-27	Closed	-$29K	–	61
2016 Q2	$29K	Hold	27	–	–	0.01%	65
2016 Q1	$36K	Hold	27	–	–	0.02%	62
2015 Q4	$30K	Buy	+27	New	+$47.8K	0.01%	64

Other funds holding APTO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SIM

Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

Callan Capital's APTO Position: Q3 2016 in Review

Callan Capital sold out of Aptose Biosciences, Inc. (APTO) in Q3 2016, closing a stake of 27 shares — an estimated $29K sold.

Callan Capital first reported a position in APTO in Q4 2015 and held it in 3 quarters. The position peaked at $36K in Q1 2016. 9 funds tracked by Wall St. Rank hold APTO as of Q3 2016.

Callan Capital reported no remaining Aptose Biosciences, Inc. position as of Q3 2016 after selling out during the quarter.
Callan Capital sold 27 Aptose Biosciences, Inc. shares in Q3 2016, an estimated $29K.
Callan Capital first reported a position in Aptose Biosciences, Inc. in Q4 2015 and held it in 3 quarters.
Callan Capital's Aptose Biosciences, Inc. position peaked at $36K in Q1 2016.
9 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2016.

Based on Callan Capital's 13F filing for Q3 2016, filed 15 Nov 2016.